Mantle Cell Lymphoma | Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma (Companion Faculty Lecture)
Research To Practice | Oncology Videos · Dr. Neil Love
August 31, 202321m 28s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring a slide presentation and related discussion from Dr Michael Wang, including the following topics:
- Overview of Bruton tyrosine kinase (BTK) inhibitors and clinical data establishing the efficacy of these agents for mantle cell lymphoma (MCL) (0:00)
- Clinical investigation of ibrutinib in the front-line setting; results from the Phase III SHINE trial and voluntary market withdrawal of ibrutinib for MCL (4:36)
- Phase III TRIANGLE trial of ibrutinib combined with chemotherapy as upfront therapy for younger patients with MCL; role of autologous stem cell transplant (11:14)
- Acalabrutinib and zanubrutinib for the treatment of relapsed/refractory (R/R) MCL (14:16)
- Key findings from the BRUIN trial leading to the FDA approval of pirtobrutinib for R/R MCL (16:23)